A Phase II Clinical Trial to Study the Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma Refractory to Checkpoint Inhibitors
Latest Information Update: 23 Feb 2023
At a glance
- Drugs Cabozantinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms CABO_HCC
- 21 Jan 2023 Results presented at the 2023 Gastrointestinal Cancers Symposium
- 27 Jun 2022 Status changed from recruiting to active, no longer recruiting.
- 13 Jan 2021 Status changed from not yet recruiting to recruiting.